Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation

Experimental Cell Research

Volumn 312, Issue 10, 2006, Pages 1909-1923

  Nguyen, Aaron N ^a   Stebbins, Elizabeth G ^a   Henson, Margaret ^a   O'Young, Gilbert ^a   Choi, Sun J ^b   Quon, Diana ^a   Damm, Debby ^a   Reddy, Mamatha ^a   Ma, Jing Y ^a   Haghnazari, Edwin ^a   Kapoun, Ann M ^a   Medicherla, Satyanarayana ^a   Protter, Andy ^a   Schreiner, George F ^a   Kurihara, Noriyoshi ^b   Anderson, Judy ^b   Roodman, G David ^b,c   Navas, Tony A ^a   Higgins, Linda S ^a  

^a SCIOS INC   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Bone marrow microenvironment; CCL8; Cell adhesion; Chemokines; CXCL10; IL 6; Osteoclast formation; p38 MAPK inhibitor; SCIO 469; VEGF

Indexed keywords

CHEMOKINE; COLONY STIMULATING FACTOR 1; DIMETHYL SULFOXIDE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN G; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 11; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; NEUTRALIZING ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR; SCIO 469; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ARTICLE; BONE MARROW; CELL ADHESION; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG INHIBITION; HUMAN; HUMAN CELL; MICROENVIRONMENT; MULTIPLE MYELOMA; OSTEOCLAST; PRIORITY JOURNAL; STROMA CELL;

EID: 33646853556     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2006.02.026     Document Type: Article

References (62)

1. Bataille R., Chappard D., Marcelli C., Dessauw P., Sany J., Baldet P., and Alexandre C. Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease. J. Clin. Oncol. 7 (1989) 1909-1914
2. Bataille R., Manolagas S.C., and Berenson J.R. Pathogenesis and management of bone lesions in multiple myeloma. Hematol. Oncol. Clin. North Am. 11 (1997) 349-361
3. Anderson K.C., Shaughnessy Jr. J.D., Barlogie B., Harousseau J.L., and Roodman G.D. Multiple myeloma. Hematology (Am. Soc. Hematol. Educ. Prog.) (2002) 214-240
4. Barille-Nion S., Barlogie B., Bataille R., Bergsagel P.L., Epstein J., Fenton R.G., Jacobson J., Kuehl W.M., Shaughnessy J., and Tricot G. Advances in biology and therapy of multiple myeloma. Hematology (Am. Soc. Hematol. Educ. Prog.) (2003) 248-278
5. Dalton W.S. Drug resistance and drug development in multiple myeloma. Semin. Oncol. 29 (2002) 21-25
6. Dalton W.S. The tumor microenvironment: focus on myeloma. Cancer Treat. Rev. 29 Suppl. 1 (2003) 11-19
7. Hazlehurst L.A., Landowski T.H., and Dalton W.S. Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death. Oncogene 22 (2003) 7396-7402
8. Hallek M., Bergsagel P.L., and Anderson K.C. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 91 (1998) 3-21
9. Tricot G. New insights into role of microenvironment in multiple myeloma. Lancet 355 (2000) 248-250
10. Hideshima T., and Anderson K.C. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat. Rev., Cancer 2 (2002) 927-937
11. Klein B. Cytokine, cytokine receptors, transduction signals, and oncogenes in human multiple myeloma. Semin. Hematol. 32 (1995) 4-19
12. Hideshima T., Bergsagel P.L., Kuehl W.M., and Anderson K.C. Advances in biology of multiple myeloma: clinical applications. Blood 104 (2004) 607-618
13. Bataille R., Jourdan M., Zhang X.G., and Klein B. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J. Clin. Invest. 84 (1989) 2008-2011
14. Nachbaur D.M., Herold M., Maneschg A., and Huber H. Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters. Ann. Hematol. 62 (1991) 54-58
15. Podar K., Tai Y.T., Davies F.E., Lentzsch S., Sattler M., Hideshima T., Lin B.K., Gupta D., Shima Y., Chauhan D., Mitsiades C., Raje N., Richardson P., and Anderson K.C. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 98 (2001) 428-435
16. Chauhan D., Uchiyama H., Akbarali Y., Urashima M., Yamamoto K., Libermann T.A., and Anderson K.C. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 87 (1996) 1104-1112
17. Gupta D., Treon S.P., Shima Y., Hideshima T., Podar K., Tai Y.T., Lin B., Lentzsch S., Davies F.E., Chauhan D., Schlossman R.L., Richardson P., Ralph P., Wu L., Payvandi F., Muller G., Stirling D.I., and Anderson K.C. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 15 (2001) 1950-1961
18. Hideshima T., Richardson P., Chauhan D., Palombella V.J., Elliott P.J., Adams J., and Anderson K.C. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 61 (2001) 3071-3076
19. Bataille R., Barlogie B., Lu Z.Y., Rossi J.F., Lavabre-Bertrand T., Beck T., Wijdenes J., Brochier J., and Klein B. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 86 (1995) 685-691
20. Tassone P., Galea E., Forciniti S., Tagliaferri P., and Venuta S. The IL-6 receptor super-antagonist Sant7 enhances antiproliferative and apoptotic effects induced by dexamethasone and zoledronic acid on multiple myeloma cells. Int. J. Oncol. 21 (2002) 867-873
21. Podar K., Catley L.P., Tai Y.T., Shringarpure R., Carvalho P., Hayashi T., Burger R., Schlossman R.L., Richardson P.G., Pandite L.N., Kumar R., Hideshima T., Chauhan D., and Anderson K.C. GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment. Blood 103 (2004) 3474-3479
22. Dalton W.S. The tumor microenvironment as a determinant of drug response and resistance. Drug Resist. Updat. 2 (1999) 285-288
23. Filella X., Blade J., Guillermo A.L., Molina R., Rozman C., and Ballesta A.M. Cytokines (IL-6, TNF-alpha, IL-1alpha) and soluble interleukin-2 receptor as serum tumor markers in multiple myeloma. Cancer Detect. Prev. 20 (1996) 52-56
24. Sati H.I., Greaves M., Apperley J.F., Russell R.G., and Croucher P.I. Expression of interleukin-1beta and tumour necrosis factor-alpha in plasma cells from patients with multiple myeloma. Br. J. Haematol. 104 (1999) 350-357
25. Hideshima T., Chauhan D., Schlossman R., Richardson P., and Anderson K.C. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 20 (2001) 4519-4527
26. Kurihara N., Bertolini D., Suda T., Akiyama Y., and Roodman G.D. IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release. J. Immunol. 144 (1990) 4226-4230
27. Devlin R.D., Reddy S.V., Savino R., Ciliberto G., and Roodman G.D. IL-6 mediates the effects of IL-1 or TNF, but not PTHrP or 1,25(OH)2D3, on osteoclast-like cell formation in normal human bone marrow cultures. J. Bone. Miner. Res. 13 (1998) 393-399
28. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., Elliott R., Colombero A., Elliott G., Scully S., Hsu H., Sullivan J., Hawkins N., Davy E., Capparelli C., Eli A., Qian Y.X., Kaufman S., Sarosi I., Shalhoub V., Senaldi G., Guo J., Delaney J., and Boyle W.J. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93 (1998) 165-176
29. Pearse R.N., Sordillo E.M., Yaccoby S., Wong B.R., Liau D.F., Colman N., Michaeli J., Epstein J., and Choi Y. Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 11581-11586
30. Abe M., Hiura K., Wilde J., Moriyama K., Hashimoto T., Ozaki S., Wakatsuki S., Kosaka M., Kido S., Inoue D., and Matsumoto T. Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood 100 (2002) 2195-2202
31. Han J.H., Choi S.J., Kurihara N., Koide M., Oba Y., and Roodman G.D. Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. Blood 97 (2001) 3349-3353
32. Platanias L.C. Map kinase signaling pathways and hematologic malignancies. Blood 101 (2003) 4667-4679
33. Hideshima T., Akiyama M., Hayashi T., Richardson P., Schlossman R., Chauhan D., and Anderson K.C. Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. Blood 101 (2003) 703-705
34. Hideshima T., Podar K., Chauhan D., Ishitsuka K., Mitsiades C., Tai Y.T., Hamasaki M., Raje N., Hideshima H., Schreiner G., Nguyen A.N., Navas T., Munshi N.C., Richardson P.G., Higgins L.S., and Anderson K.C. p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene 23 (2004) 8766-8776
35. Hideshima T., Chauhan D., Hayashi T., Akiyama M., Mitsiades N., Mitsiades C., Podar K., Munshi N.C., Richardson P.G., and Anderson K.C. Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene 22 (2003) 8386-8393
36. Kapoun A.M., Liang F., O'Young G., Damm D.L., Quon D., White R.T., Munson K., Lam A., Schreiner G.F., and Protter A.A. B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ. Res. 94 (2004) 453-461
37. Yang Y., Dudoit S., Luu P., Lin D., Peng V., Ngai J., and Speed T. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res. 30 (2002) e15
38. Landry J., and Huot J. Modulation of actin dynamics during stress and physiological stimulation by a signaling pathway involving p38 MAP kinase and heat-shock protein 27. Biochem. Cell. Biol. 73 (1995) 703-707
39. Beyaert R., Cuenda A., Vanden Berghe W., Plaisance S., Lee J.C., Haegeman G., Cohen P., and Fiers W. The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis response to tumor necrosis factor. EMBO J. 15 (1996) 1914-1923
40. Klein B., Zhang X.G., Jourdan M., Content J., Houssiau F., Aarden L., Piechaczyk M., and Bataille R. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 73 (1989) 517-526
41. Imhof B.A., and Aurrand-Lions M. Adhesion mechanisms regulating the migration of monocytes. Nat. Rev., Immunol. 4 (2004) 432-444
42. Matsumoto M., Sudo T., Saito T., Osada H., and Tsujimoto M. Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL). J. Biol. Chem. 275 (2000) 31155-31161
43. Lee S.E., Woo K.M., Kim S.Y., Kim H.M., Kwack K., Lee Z.H., and Kim H.H. The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation. Bone 30 (2002) 71-77
44. Damiano J.S., Cress A.E., Hazlehurst L.A., Shtil A.A., and Dalton W.S. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 93 (1999) 1658-1667
45. Oba Y., Lee J.W., Ehrlich L.A., Chung H.Y., Jelinek D.F., Callander N.S., Horuk R., Choi S.J., and Roodman G.D. MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells. Exp. Hematol. 33 (2005) 272-278
46. Secchiero P., Corallini F., di Iasio M.G., Gonelli A., Barbarotto E., and Zauli G. TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release. Blood 105 (2005) 3413-3419
47. Zauli G., Rimondi E., Nicolin V., Melloni E., Celeghini C., and Secchiero P. TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF. Blood 104 (2004) 2044-2050
48. Gahrton G., Tura S., Ljungman P., Belanger C., Brandt L., Cavo M., Facon T., Granena A., Gore M., Gratwohl A., Lowenberg B., Nikoskelainen J., Reiffers J.J., Samson D., Verdonck L., and Volin L. Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. N. Engl. J. Med. 325 (1991) 1267-1273
49. Attal M., Harousseau J.L., Stoppa A.M., Sotto J.J., Fuzibet J.G., Rossi J.F., Casassus P., Maisonneuve H., Facon T., Ifrah N., Payen C., and Bataille R. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N. Engl. J. Med. 335 (1996) 91-97
50. Barlogie B., Jagannath S., Vesole D.H., Naucke S., Cheson B., Mattox S., Bracy D., Salmon S., Jacobson J., Crowley J., and Tricot G. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 89 (1997) 789-793
51. Cavo M., Bandini G., Benni M., Gozzetti A., Ronconi S., Rosti G., Zamagni E., Lemoli R.M., Bonini A., Belardinelli A., Motta M.R., Rizzi S., and Tura S. High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma. Bone Marrow Transplant. 22 (1998) 27-32
52. Suda T., Nakamura I., Jimi E., and Takahashi N. Regulation of osteoclast function. J. Bone Miner. Res. 12 (1997) 869-879
53. Merrell M., Suarez-Cuervo C., Harris K.W., Vaananen H.K., and Selander K.S. Bisphosphonate induced growth inhibition of breast cancer cells is augmented by p38 inhibition. Breast Cancer Res. Treat. 81 (2003) 231-241
54. Tian E., Zhan F., Walker R., Rasmussen E., Ma Y., Barlogie B., and Shaughnessy Jr. J.D. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N. Engl. J. Med. 349 (2003) 2483-2494
55. Canalis E., Economides A.N., and Gazzerro E. Bone morphogenetic proteins, their antagonists, and the skeleton. Endocr. Rev. 24 (2003) 218-235
56. Westendorf J.J., Kahler R.A., and Schroeder T.M. Wnt signaling in osteoblasts and bone diseases. Gene 341 (2004) 19-39
57. Giuliani N., Colla S., Morandi F., Lazzaretti M., Sala R., Bonomini S., Grano M., Colucci S., Svaldi M., and Rizzoli V. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 106 (2005) 2472-2483
58. Kuehl W.M., and Bergsagel P.L. Multiple myeloma: evolving genetic events and host interactions. Nat. Rev., Cancer 2 (2002) 175-187
59. Yaccoby S., Wezeman M.J., Henderson A., Cottler-Fox M., Yi Q., Barlogie B., and Epstein J. Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Res. 64 (2004) 2016-2023
60. Yaccoby S., Pearse R.N., Johnson C.L., Barlogie B., Choi Y., and Epstein J. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br. J. Haematol. 116 (2002) 278-290
61. Dhodapkar M.V., Singh J., Mehta J., Fassas A., Desikan K.R., Perlman M., Munshi N.C., and Barlogie B. Anti-myeloma activity of pamidronate in vivo. Br. J. Haematol. 103 (1998) 530-532
62. Berenson J.R., Lichtenstein A., Porter L., Dimopoulos M.A., Bordoni R., George S., Lipton A., Keller A., Ballester O., Kovacs M.J., Blacklock H.A., Bell R., Simeone J., Reitsma D.J., Heffernan M., Seaman J., and Knight R.D. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N. Engl. J. Med. 334 (1996) 488-493